ReviewChinese medical journal2017
Advances in Pathobiology of Primary Central Nervous System Lymphoma.
Review in Chinese medical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Primary central nervous system T-cell lymphoma: a single-centre retrospective study and literature review.BMJ neurology open · 2026Article
- Advances in CAR-T therapy for central nervous system lymphoma.Frontiers in immunology · 2026Review
- A study on the variation of cytokine and electrolyte levels in rhesus macaques, cynomolgus monkeys, and Assamese macaques.Animal models and experimental medicine · 2025Article
- Presentation of extranodal NK/T-cell lymphoma as a pituitary mass: A case report and review of the literature.Surgical neurology international · 2025Article
- Article
- Retrospective Evaluation of Cases Undergoing Stereotaxic Brain Biopsy.Asian journal of neurosurgery · 2023Article
- Current Indications for Intraarterial Chemotherapy in Neurointerventional Surgery.Stroke (Hoboken, N.J.) · 2023Review
- Neprilysin expression and functions in development, ageing and disease.Mechanisms of ageing and development · 2020Review
- Diagnostic and therapeutic challenges in primary vitreoretinal lymphoma: a practical clinical approach.Romanian journal of ophthalmologyReview
- Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.Basic and clinical neuroscienceArticle
- Outcome and Prognostic Factors of Primary Central Nervous System Lymphoma in Southern Thailand.Asian journal of neurosurgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePrimary central nervous system lymphoma (PCNSL) is a specific type of non-Hodgkin lymphoma with poor prognosis. The rare incidence of this disease and difficulty to obtain sufficient tissue material impede deep research into PCNSL. However, application of modern molecular techniques makes it possible to find biological characteristics exclusive to PCNSL. Therefore, we systematically reviewed the latest research progress on biological characteristics and pathogenesis of PCNSL. DATA SOURCES: The data analyzed in this review were from the articles listed in PubMed database. STUDY SELECTION: Articles focusing on the biology of PCNSL at the cytogenetic or molecular level were reviewed, including clinical, basic research, and review articles.
resultsWith respect to histopathology, perivascular growth pattern and reactive perivascular T-cell infiltration are regarded as typical histopathological manifestations of tumor cells in PCNSL. Moreover, tumor cells of PCNSL predominantly express an activated B-cell-like phenotype, including CD10- BCL-6+ MUM1+, CD10- BCL-6- MUM1+, and CD10- BCL-6- MUM1-. On the molecular level, some molecular and genetic alterations may contribute to malignant transformation, including mutations of proto-oncogenes and tumor suppressor genes, gains and losses of genetic material, as well as aberrant activation of some important signaling pathways, such as nuclear factor-κB and JAK/STAT pathway.
conclusionsThe integrated molecular mechanisms involved in pathogenesis of PCNSL are not well understood. The important biomarkers indicating prognosis are not identified. Multicenter studies should be carried out to elucidate pathogenesis of PCNSL to find novel and effective therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.